Vildagliptin versus Standard Therapy on Coronary flow reserve in Type2 Diabetes Mellitus-Juntendo

Trial Profile

Vildagliptin versus Standard Therapy on Coronary flow reserve in Type2 Diabetes Mellitus-Juntendo

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2015

At a glance

  • Drugs Vildagliptin (Primary) ; Antihyperglycaemics
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms VIVALDI
  • Most Recent Events

    • 06 Jul 2015 Status changed from recruiting to completed as per University Hospital Medical Information Network - Japan record.
    • 13 Jul 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top